NM_003376.6:c.188G>T

Variant summary

Our verdict is Likely benign. The variant received -6 ACMG points: 0P and 6B. BP4_ModerateBS2

The NM_003376.6(VEGFA):​c.188G>T​(p.Arg63Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000431 in 1,392,476 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: not found (cov: 33)
Exomes 𝑓: 0.0000043 ( 0 hom. )

Consequence

VEGFA
NM_003376.6 missense

Scores

2
2
13

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 0.730

Publications

1 publications found
Variant links:
Genes affected
VEGFA (HGNC:12680): (vascular endothelial growth factor A) This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -6 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.1279557).
BS2
High AC in GnomAdExome4 at 6 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
VEGFANM_003376.6 linkc.188G>T p.Arg63Leu missense_variant Exon 1 of 8 ENST00000672860.3 NP_003367.4 P15692-13

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
VEGFAENST00000672860.3 linkc.188G>T p.Arg63Leu missense_variant Exon 1 of 8 NM_003376.6 ENSP00000500082.3 P15692-13A0A5F9ZH41

Frequencies

GnomAD3 genomes
Cov.:
33
GnomAD2 exomes
AF:
0.0000138
AC:
2
AN:
145258
AF XY:
0.0000129
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000431
AC:
6
AN:
1392476
Hom.:
0
Cov.:
36
AF XY:
0.00000437
AC XY:
3
AN XY:
686712
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
30742
American (AMR)
AF:
0.00
AC:
0
AN:
35372
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
25062
East Asian (EAS)
AF:
0.00
AC:
0
AN:
35328
South Asian (SAS)
AF:
0.0000638
AC:
5
AN:
78406
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
48278
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
4142
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
1077488
Other (OTH)
AF:
0.0000173
AC:
1
AN:
57658
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.433
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
Cov.:
33

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not specified Uncertain:1
Oct 25, 2023
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.188G>T (p.R63L) alteration is located in exon 1 (coding exon 1) of the VEGFA gene. This alteration results from a G to T substitution at nucleotide position 188, causing the arginine (R) at amino acid position 63 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
-0.22
T
BayesDel_noAF
Benign
-0.56
CADD
Benign
20
DANN
Benign
0.97
DEOGEN2
Benign
0.25
T;.;.;T;.;.;.;.;.;T;.;.;.;T;.
Eigen
Benign
-0.46
Eigen_PC
Benign
-0.34
FATHMM_MKL
Uncertain
0.76
D
LIST_S2
Benign
0.81
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
M_CAP
Uncertain
0.18
D
MetaRNN
Benign
0.13
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
-1.1
T
PhyloP100
0.73
PrimateAI
Pathogenic
0.90
D
PROVEAN
Benign
-0.69
N;.;N;N;.;.;.;.;.;N;N;.;N;N;N
REVEL
Benign
0.016
Sift
Benign
0.18
T;.;T;T;.;.;.;.;.;T;T;.;T;T;T
Sift4G
Pathogenic
0.0
D;.;D;D;D;D;.;D;.;D;D;D;D;D;D
Polyphen
0.052, 0.0060, 0.0050, 0.011
.;.;.;.;B;B;.;B;B;.;.;.;.;.;.
MutPred
0.33
Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);Loss of MoRF binding (P = 0.0057);
MVP
0.22
ClinPred
0.64
D
GERP RS
3.0
PromoterAI
-0.018
Neutral
RBP_binding_hub_radar
0.97
RBP_regulation_power_radar
2.0
gMVP
0.22
Mutation Taster
=300/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1202242670; hg19: chr6-43738631; API